{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:25:54Z","timestamp":1707524754256},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,30]]},"DOI":"10.7759\/cureus.33134","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T13:42:50Z","timestamp":1672407770000},"source":"Crossref","is-referenced-by-count":0,"title":["Systemic Bacillus Calmette-Gu\u00e9rin (BCG) Infection With Renal Involvement: A Rare Complication of BCG Immunotherapy"],"prefix":"10.7759","author":[{"given":"Raquel","family":"Afonso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Fontes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Esteves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1086\/314064","article-title":"Efficacy and safety of bacille Calmette-Gu\u00e9rin immunotherapy in superficial bladder cancer","volume":"31","author":"Lamm DL","year":"2000","unstructured":"Lamm DL. Efficacy and safety of bacille Calmette-Gu\u00e9rin immunotherapy in superficial bladder cancer. Clin Infect Dis. 2000, 31:S86-90. 10.1086\/314064","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2019.10.001","article-title":"Disseminated bacillus Calmette-Gu\u00e9rin (BCG) infection with pulmonary and renal involvement: a rare complication of BCG immunotherapy. A case report and narrative review","volume":"26","author":"Marques M","year":"2020","unstructured":"Marques M, Vazquez D, Sousa S, Mesquita G, Duarte M, Ferreira R. Disseminated bacillus Calmette-Gu\u00e9rin (BCG) infection with pulmonary and renal involvement: a rare complication of BCG immunotherapy. A case report and narrative review. Pulmonology. 2020, 26:346-52. 10.1016\/j.pulmoe.2019.10.001","journal-title":"Pulmonology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-243641","article-title":"Systemic infection following intravesical therapy with BCG","volume":"9","author":"Oliveira AA","year":"2021","unstructured":"Oliveira AA, Morais J, Ribeiro J, Gouveia PF. Systemic infection following intravesical therapy with BCG. BMJ Case Rep. 2021, 9:e243641. 10.1136\/bcr-2021-243641","journal-title":"BMJ Case Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.983082","article-title":"Immunological basis in the pathogenesis and treatment of bladder cancer","volume":"11","author":"Thompson DB","year":"2015","unstructured":"Thompson DB, Siref LE, Feloney MP, Hauke RJ, Agrawal DK. Immunological basis in the pathogenesis and treatment of bladder cancer. Expert Rev Clin Immunol. 2015, 11:265-79. 10.1586\/1744666X.2015.983082","journal-title":"Expert Rev Clin Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.4.616","article-title":"Granulomatous hepatitis caused by Bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation","volume":"38","author":"Leebeek FW","year":"1996","unstructured":"Leebeek FW, Ouwendijk RJ, Kolk AH, Dees A, Meek JC, Nienhuis JE, Dingemans-Dumas AM. Granulomatous hepatitis caused by Bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation. Gut. 1996, 38:616-8. 10.1136\/gut.38.4.616","journal-title":"Gut"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000052381","article-title":"BCG intravesical instillations: recommendations for side-effects management","volume":"37","author":"Rischmann P","year":"2000","unstructured":"Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG intravesical instillations: recommendations for side-effects management. Eur Urol. 2000, 37:33-6. 10.1159\/000052381","journal-title":"Eur Urol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm DL","year":"1992","unstructured":"Lamm DL, van der Meijden PM, Morales A, et al.. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992, 147:596-600. 10.1016\/s0022-5347(17)37316-0","journal-title":"J Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2478\/jtim-2019-0007","article-title":"Favorable outcome in a patient with systemic bcgitis after intra-bladder instillation of Calmette-Guerin Bacillus highlighting the importance of making the correct diagnosis in this rare form of sepsis","volume":"7","author":"Attou R","year":"2019","unstructured":"Attou R, Albrich T, Kadou J, Redant S, Honor\u00e9 PM, De Bels D. Favorable outcome in a patient with systemic bcgitis after intra-bladder instillation of Calmette-Guerin Bacillus highlighting the importance of making the correct diagnosis in this rare form of sepsis. J Transl Int Med. 2019, 7:34-8. 10.2478\/jtim-2019-0007","journal-title":"J Transl Int Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.04.006","article-title":"Differences between a probable and proven BCG infection following intravesical instillations: 16 years experience in a tertiary care hospital","volume":"85","author":"Gonz\u00e1lez-Del Vecchio M","year":"2016","unstructured":"Gonz\u00e1lez-Del Vecchio M, Ru\u00edz-Serrano MJ, Gij\u00f3n P, et al.. Differences between a probable and proven BCG infection following intravesical instillations: 16 years experience in a tertiary care hospital. Diagn Microbiol Infect Dis. 2016, 85:338-43. 10.1016\/j.diagmicrobio.2016.04.006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4236\/aid.2015.54027","article-title":"BCG infection after bladder cancer treatment\u20143 clinical case reports","volume":"5","author":"Alves J","year":"2015","unstructured":"Alves J, Ramos A, Carvalho T, et al.. BCG infection after bladder cancer treatment\u20143 clinical case reports. Adv Infect Dis. 2015, 5:218-21. 10.4236\/aid.2015.54027","journal-title":"Adv Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.11.037","article-title":"BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: a systematic review","volume":"39","author":"Cabas P","year":"2021","unstructured":"Cabas P, Rizzo M, Giuffr\u00e8 M, et al.. BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: a systematic review. Urol Oncol. 2021, 39:85-92. 10.1016\/j.urolonc.2020.11.037","journal-title":"Urol Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TAT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk M","year":"2020","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM, et al.. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TAT1 and carcinoma in situ) - 2019 update. Eur Urol. 2020, 76:639-57. 10.1016\/j.eururo.2019.08.016","journal-title":"Eur Urol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19145","article-title":"Management of complications of Bacillus Calmette-Gu\u00e9rin immunotherapy in the treatment of bladder cancer","volume":"34","author":"Huang TC","year":"2000","unstructured":"Huang TC. Management of complications of Bacillus Calmette-Gu\u00e9rin immunotherapy in the treatment of bladder cancer. Ann Pharmacother. 2000, 34:529-32. 10.1345\/aph.19145","journal-title":"Ann Pharmacother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000119","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature","volume":"93","author":"P\u00e9rez-Jacoiste As\u00edn MA","year":"2014","unstructured":"P\u00e9rez-Jacoiste As\u00edn MA, Fern\u00e1ndez-Ruiz M, L\u00f3pez-Medrano F, et al.. Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore). 2014, 93:236-54. 10.1097\/MD.0000000000000119","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/130336-systemic-bacillus-calmette-gurin-bcg-infection-with-renal-involvement-a-rare-complication-of-bcg-immunotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:44Z","timestamp":1707508124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/130336-systemic-bacillus-calmette-gurin-bcg-infection-with-renal-involvement-a-rare-complication-of-bcg-immunotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.33134","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,30]]}}}